Pyrazole-based arylalkyne cathepsin S inhibitors. Part II: optimization of cellular potency.

[1]  B. Samuelsson,et al.  Solid-phase parallel synthesis and SAR of 4-amidofuran-3-one inhibitors of cathepsin S: effect of sulfonamides P3 substituents on potency and selectivity. , 2009, Bioorganic & medicinal chemistry.

[2]  S. Bevan,et al.  Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-cyanopyrimidines. Part 2. , 2008, Bioorganic & medicinal chemistry letters.

[3]  S. Bevan,et al.  Discovery of orally bioavailable cathepsin S inhibitors for the reversal of neuropathic pain. , 2008, Journal of medicinal chemistry.

[4]  T. Kanazawa,et al.  4-Amino-2-cyanopyrimidines: novel scaffold for nonpeptidic cathepsin S inhibitors. , 2008, Bioorganic & Medicinal Chemistry Letters.

[5]  T. Kanazawa,et al.  Discovery of selective and nonpeptidic cathepsin S inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[6]  A. Ray,et al.  Cysteine cathepsin S as an immunomodulatory target: present and future trends , 2008, Expert opinion on therapeutic targets.

[7]  Wen Jiang,et al.  Pyrazole-based cathepsin S inhibitors with improved cellular potency. , 2007, Bioorganic & medicinal chemistry letters.

[8]  M. Percival,et al.  The identification of potent, selective, and bioavailable cathepsin S inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[9]  S. Bevan,et al.  Role of the cysteine protease cathepsin S in neuropathic hyperalgesia , 2007, PAIN.

[10]  S. Bevan,et al.  Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain , 2007, Proceedings of the National Academy of Sciences.

[11]  Jennifer L. Harris,et al.  Synthesis and SAR of succinamide peptidomimetic inhibitors of cathepsin S. , 2007, Bioorganic & medicinal chemistry letters.

[12]  M. Hao,et al.  Identification of a novel class of succinyl-nitrile-based Cathepsin S inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[13]  G. Spraggon,et al.  Characterization and optimization of selective, nonpeptidic inhibitors of cathepsin S with an unprecedented binding mode. , 2007, Journal of medicinal chemistry.

[14]  O. Vasiljeva,et al.  Emerging roles of cysteine cathepsins in disease and their potential as drug targets. , 2007, Current pharmaceutical design.

[15]  Jun Li,et al.  Synthesis and SAR of arylaminoethyl amides as noncovalent inhibitors of cathepsin S: P3 cyclic ethers. , 2006, Bioorganic & medicinal chemistry letters.

[16]  Jun Li,et al.  Arylaminoethyl carbamates as a novel series of potent and selective cathepsin S inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[17]  Scott Lesley,et al.  Identification of selective, nonpeptidic nitrile inhibitors of cathepsin s using the substrate activity screening method. , 2006, Journal of medicinal chemistry.

[18]  Cheryl A. Grice,et al.  The SAR of 4-substituted (6,6-bicyclic) piperidine cathepsin S inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[19]  Jun Li,et al.  Synthesis and evaluation of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 3: heterocyclic P3. , 2006, Bioorganic & medicinal chemistry letters.

[20]  Jennifer L. Harris,et al.  Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl. , 2006, Bioorganic & Medicinal Chemistry Letters.

[21]  Jennifer L. Harris,et al.  Design and synthesis of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 1. , 2005, Bioorganic & medicinal chemistry letters.

[22]  J. Falgueyret,et al.  Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. , 2005, Journal of medicinal chemistry.

[23]  A. Rudensky,et al.  The lysosomal cysteine proteases in MHC class II antigen presentation , 2005, Immunological reviews.

[24]  Jianmei Wei,et al.  Discovery and SAR studies of a novel series of noncovalent cathepsin S inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[25]  Mary Pat Beavers,et al.  Nonpeptidic, noncovalent inhibitors of the cysteine protease cathepsin S. , 2004, Journal of medicinal chemistry.

[26]  Vincent Leroy,et al.  Cathepsin S inhibitors , 2004 .

[27]  Lars Karlsson,et al.  Identification of a Potent and Selective Noncovalent Cathepsin S Inhibitor , 2004, Journal of Pharmacology and Experimental Therapeutics.

[28]  Makoto Naito,et al.  Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. , 2003, The Journal of clinical investigation.

[29]  Jeffrey D Peterson,et al.  The design of potent hydrazones and disulfides as cathepsin S inhibitors. , 2003, Bioorganic & medicinal chemistry.

[30]  Yong Wang,et al.  Design and synthesis of dipeptide nitriles as reversible and potent Cathepsin S inhibitors. , 2002, Journal of medicinal chemistry.

[31]  M. Blaskovich,et al.  Recent discovery and development of protein tyrosine phosphatase inhibitors , 2002 .

[32]  Kooil Kang,et al.  Recent developments of cathepsin inhibitors and their selectivity , 2002 .

[33]  H Martin,et al.  The design of phenylglycine containing benzamidine carboxamides as potent and selective inhibitors of factor Xa. , 2001, Bioorganic & medicinal chemistry letters.

[34]  K. Yokogawa,et al.  Uptake of imipramine in rat liver lysosomes in vitro and its inhibition by basic drugs. , 2000, The Journal of pharmacology and experimental therapeutics.

[35]  A. Rudensky,et al.  Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. , 1999, Immunity.

[36]  K. Kawamura,et al.  Synthesis and activity of optical isomers of nipradilol. , 1987, Chemical and pharmaceutical bulletin.

[37]  K. Clément,et al.  Emerging role of cathepsin S in obesity and its associated diseases , 2007, Clinical chemistry and laboratory medicine.